5921 |
8CY9 |
E_B |
1-23 VHH |
SARS-CoV-2 spike glycoprotein |
Severe acute respiratory syndrome coronavirus 2, Lama glama |
EM |
2.9 | 10.1016/j.celrep.2022.111004 |
5922 |
8CY9 |
F_C |
1-23 VHH |
SARS-CoV-2 spike glycoprotein |
Severe acute respiratory syndrome coronavirus 2, Lama glama |
EM |
2.9 | 10.1016/j.celrep.2022.111004 |
5923 |
8CYA |
D_C |
2-67 VHH |
SARS-CoV-2 spike glycoprotein |
Severe acute respiratory syndrome coronavirus 2, Lama glama |
EM |
2.7 | 10.1016/j.celrep.2022.111004 |
5924 |
8CYA |
F_B |
2-67 VHH |
SARS-CoV-2 spike glycoprotein |
Severe acute respiratory syndrome coronavirus 2, Lama glama |
EM |
2.7 | 10.1016/j.celrep.2022.111004 |
5925 |
8CYA |
E_A |
2-67 VHH |
SARS-CoV-2 spike glycoprotein |
Severe acute respiratory syndrome coronavirus 2, Lama glama |
EM |
2.7 | 10.1016/j.celrep.2022.111004 |
5926 |
8CYB |
D_A |
1-8 VHH |
SARS-CoV-2 spike glycoprotein |
Severe acute respiratory syndrome coronavirus 2, Lama glama |
EM |
2.7 | 10.1016/j.celrep.2022.111004 |
5927 |
8CYC |
D_A |
2-34 VHH |
SARS-CoV-2 spike glycoprotein |
Severe acute respiratory syndrome coronavirus 2, Lama glama |
EM |
2.9 | 10.1016/j.celrep.2022.111004 |
5928 |
8CYC |
E_B |
2-34 VHH |
SARS-CoV-2 spike glycoprotein |
Severe acute respiratory syndrome coronavirus 2, Lama glama |
EM |
2.9 | 10.1016/j.celrep.2022.111004 |
5929 |
8CYC |
F_C |
2-34 VHH |
SARS-CoV-2 spike glycoprotein |
Severe acute respiratory syndrome coronavirus 2, Lama glama |
EM |
2.9 | 10.1016/j.celrep.2022.111004 |
5930 |
8CYD |
F_A |
2-45 VHH |
SARS-CoV-2 spike glycoprotein |
Severe acute respiratory syndrome coronavirus 2, Lama glama |
EM |
2.6 | 10.1016/j.celrep.2022.111004 |
5931 |
8CYD |
D_B |
2-45 VHH |
SARS-CoV-2 spike glycoprotein |
Severe acute respiratory syndrome coronavirus 2, Lama glama |
EM |
2.6 | 10.1016/j.celrep.2022.111004 |
5932 |
8CYD |
E_C |
2-45 VHH |
SARS-CoV-2 spike glycoprotein |
Severe acute respiratory syndrome coronavirus 2, Lama glama |
EM |
2.6 | 10.1016/j.celrep.2022.111004 |
5933 |
8CYH |
HL_M |
A12 Fab |
Human mesothelin |
Homo sapiens |
XRD |
3.38 | 10.3389/fddsv.2023.1216516 |
5934 |
8CYJ |
C_R |
2-10 VHH |
SARS-CoV-2 spike glycoprotein |
Lama glama, Severe acute respiratory syndrome coronavirus 2 |
EM |
3.6 | 10.1016/j.celrep.2022.111004 |
5935 |
8CYJ |
A_R |
2-67 VHH |
SARS-CoV-2 spike glycoprotein |
Lama glama, Severe acute respiratory syndrome coronavirus 2 |
EM |
3.6 | 10.1016/j.celrep.2022.111004 |
5936 |
8CYJ |
D_R |
2-62 VHH |
SARS-CoV-2 spike glycoprotein |
Lama glama, Severe acute respiratory syndrome coronavirus 2 |
EM |
3.6 | 10.1016/j.celrep.2022.111004 |
5937 |
8CYJ |
B_R |
1-25 VHH |
SARS-CoV-2 spike glycoprotein |
Lama glama, Severe acute respiratory syndrome coronavirus 2 |
EM |
3.6 | 10.1016/j.celrep.2022.111004 |
5938 |
8CZ5 |
HL_A |
2D9 Fab |
Rabbit hemorrhagic disease virus GI.2 (N11 strain) protruding domain (RHDV N11 P domain) |
Lagovirus, Mus musculus |
XRD |
2.65 | 10.1128/jvi.01217-22 |
5939 |
8CZ8 |
A_E |
anetumab scFv |
Human mesothelin |
Homo sapiens |
XRD |
2.6 | 10.3389/fddsv.2023.1216516 |
5940 |
8CZ8 |
C_M |
anetumab scFv |
Human mesothelin |
Homo sapiens |
XRD |
2.6 | 10.3389/fddsv.2023.1216516 |